Akanda Corp. is an international medical cannabis and wellness platform company. The Company’s portfolio includes Canmart Ltd. (CanMart), a United Kingdom-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the United Kingdom. Canmart is a licensed importer and distributor of CBD Extraction for Medicinal Purposes (CBPMs) in the United Kingdom.
CanMart holds a controlled drug license issued by the Home Office to possess and supply CBPMs in the United Kingdom. The Company's seed-to-patient supply chain also includes partnerships Cellen Life Sciences' Leva Clinic, a fully digital pain clinic in the United Kingdom. The Company also develops a Canadian farming property in British Columbia, including farming land and related operations and licenses.
The Company also focuses on developing tetrahydrocannabinol (THC) and cannabinoid (CBD) facilities at this site..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 53.2K | 
| Three Month Average Volume | 14.1M | 
| High Low | |
| Fifty-Two Week High | 42 USD | 
| Fifty-Two Week Low | 1.15 USD | 
| Fifty-Two Week High Date | 11 Sep 2023 | 
| Fifty-Two Week Low Date | 29 Aug 2024 | 
| Price and Volume | |
| Current Price | 1.22 USD | 
| Beta | -100,000 | 
| Relative Price Change | |
| Four Week Relative Price Change | -27.82% | 
| Thirteen Week Relative Price Change | -56.16% | 
| Twenty-Six Week Relative Price Change | -87.39% | 
| Fifty-Two Week Relative Price Change | -95.73% | 
| Year-to-Date Relative Price Change | -94.15% | 
| Price Change | |
| One Day Price Change | 4.27% | 
| Thirteen Week Price Change | -53.08% | 
| Twenty-Six Week Price Change | -86.14% | 
| Five Day Price Change | -9.63% | 
| Fifty-Two Week Price Change | -94.65% | 
| Year-to-Date Price Change | -93.08% | 
| Month-to-Date Price Change | -18.67% | 
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -27.21121 USD | 
| Book Value Per Share (Most Recent Quarter) | -27.21121 USD | 
| Tangible Book Value Per Share (Last Fiscal Year) | -54.21484 USD | 
| Tangible Book Value Per Share (Most Recent Quarter) | -54.21484 USD | 
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -52.75169 USD | 
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 19.17828 USD | 
| Revenue Per Share (Trailing Twelve Months) | 20.24794 USD | 
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD | 
| Dividend Per Share (Trailing Twelve Months) | 0 USD | 
| Dividend Per Share (5 Year) | -99999.99 USD | 
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -286.5544 USD | 
| Excluding Extraordinary Items (Trailing Twelve Months) | -286.5533 USD | 
| Normalized (Last Fiscal Year) | -67.28096 USD | 
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -286.5544 USD | 
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -286.5533 USD | 
| Including Extraordinary Items (Last Fiscal Year) | -286.5544 USD | 
| Including Extraordinary Items (Trailing Twelve Months) | -286.5533 USD | 
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.58859 USD | 
| Cash Per Share (Most Recent Quarter) | 0.58859 USD | 
| Cash Flow Per Share (Last Fiscal Year) | -248.5247 USD | 
| Cash Flow Per Share (Trailing Twelve Months) | -262.386 USD | 
| Free Cash Flow Per Share (Trailing Twelve Months) | -14.08015 USD | 
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 | 
| Cash Flow Revenue (Trailing Twelve Months) | -70 | 
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,494.18% | 
| Pretax Margin (Last Fiscal Year) | -1,494.18% | 
| Pretax Margin (5 Year) | -99,999.99% | 
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 11.64% | 
| Gross Margin (Trailing Twelve Months) | 11.64% | 
| Gross Margin (5 Year) | -99,999.99% | 
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,602.00% | 
| Operating Margin (Trailing Twelve Months) | -1,602.00% | 
| Operating Margin (5 Year) | -99,999.99% | 
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,494.18% | 
| Net Profit Margin (Trailing Twelve Months) | -1,494.18% | 
| Net Profit Margin (5 Year) | -99,999.99% | 
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% | 
| Tangible Book Value (5 Year) | -99,999.99% | 
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% | 
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -70.05% | 
| Revenue Growth (3 Year) | -99,999.99% | 
| Revenue Change (Trailing Twelve Months) | -17.55% | 
| Revenue Per Share Growth | -99,999.99% | 
| Revenue Growth (5 Year) | -99,999.99% | 
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% | 
| Total Debt (5 Year) | -99,999.99% | 
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% | 
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -79.33% | 
| EPS Change (Trailing Twelve Months) | -160.36% | 
| EPS Growth (3 Year) | -99,999.99% | 
| EPS Growth (5 Year) | -99,999.99% | 
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% | 
| EBITDA (5 Year Interim) | -99,999.99% | 
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% | 
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 | 
| Price to Tangible Book (Most Recent Quarter) | -100,000 | 
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 | 
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 | 
| Net Debt | |
| Net Debt (Most Recent Quarter) | 3.9M | 
| Net Debt (Last Fiscal Year) | 3.9M | 
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 | 
| Price to Sales (Trailing Twelve Months) | 1 | 
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 | 
| PE Normalized (Last Fiscal Year) | -100,000 | 
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 | 
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 | 
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 | 
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% | 
| Dividend Yield | -99,999.99% | 
| Current Dividend Yield | 0.00% | 
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 | 
| Price to Book (Most Recent Quarter) | -100,000 | 
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 | 
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 | 
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% | 
| Payout Ratio (Trailing Twelve Months) | -99,999.99% | 
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 0 | 
| Quick Ratio (Most Recent Quarter) | 0 | 
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 | 
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 | 
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 0 | 
| Current Ratio (Most Recent Quarter) | 0 | 
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -1,502,070 | 
| Free Cash Flow (Trailing Twelve Months) | -1,502,070 | 
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -27 | 
| Net Interest Coverage (Trailing Twelve Months) | -27 | 
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 | 
| Total Debt to Equity (Most Recent Quarter) | -100,000 | 
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -134.94% | 
| Return on Assets (Trailing Twelve Months) | -134.94% | 
| Return on Assets (5 Year) | -99,999.99% | 
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -279.79% | 
| Return on Equity (Trailing Twelve Months) | -279.79% | 
| Return on Equity (5 Year) | -99,999.99% | 
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -227.95% | 
| Return on Investment (Trailing Twelve Months) | -227.95% | 
| Return on Investment (5 Year) | -99,999.99% |